INTRODUCTION {#uog19182-sec-0005}
============

Fetal urine production begins at about 10 weeks\' gestation, when the urinary bladder can be identified as an anechoic structure within the fetal pelvis, surrounded by the two umbilical arteries[1](#uog19182-bib-0001){ref-type="ref"}. The finding of a distended urinary bladder, also known as fetal megacystis, is easily accomplished on ultrasound but difficult to manage owing to its varied etiology and uncertain evolution. In the first trimester, fetal megacystis is defined as longitudinal bladder diameter (LBD) ≥ 7 mm, and is present in 0.06% of pregnancies[2](#uog19182-bib-0002){ref-type="ref"}. Beyond the first trimester, the prevalence of megacystis remains unclear and its definition is still ambiguous[3](#uog19182-bib-0003){ref-type="ref"}.

The main cause of fetal megacystis, diagnosed in any trimester of pregnancy, is bladder outlet obstruction, also known as lower urinary tract obstruction (LUTO)[4](#uog19182-bib-0004){ref-type="ref"}, [5](#uog19182-bib-0005){ref-type="ref"}, [6](#uog19182-bib-0006){ref-type="ref"}. In cases with severe early megacystis, parents often choose to terminate the pregnancy. In less severe cases with early megacystis (LBD ≤ 12 mm) and negative work‐up, a spontaneous resolution often occurs[4](#uog19182-bib-0004){ref-type="ref"}, [6](#uog19182-bib-0006){ref-type="ref"}, [7](#uog19182-bib-0007){ref-type="ref"}. In fetuses surviving the second half of pregnancy, LUTO commonly leads to hydronephrosis, renal dysplasia and severe oligohydramnios, with a known poor prognosis. However, besides isolated LUTO, the differential diagnosis of fetal megacystis should also include chromosomal abnormalities, genetic syndromes and developmental anomalies. The wide spectrum of etiologies and prognoses makes the counseling and management of this condition particularly challenging[8](#uog19182-bib-0008){ref-type="ref"}. Given the low prevalence of fetal megacystis[9](#uog19182-bib-0009){ref-type="ref"}, [10](#uog19182-bib-0010){ref-type="ref"} and the main focus on LUTO as etiology, the other causes of enlarged fetal bladder have, thus far, been poorly investigated.

The main aim of this study was to present a comprehensive overview of the underlying etiologies and structural anomalies associated with fetal megacystis and to identify patterns of anomalies and ultrasound features related to specific complex anomalies and syndromes, beyond LUTO.

METHODS {#uog19182-sec-0006}
=======

This study was part of a large retrospective multicenter study carried out at the fetal medicine units (FMUs) of all eight academic hospitals in The Netherlands that act as referral centers for fetal anomalies detected on ultrasound examination. Data on cases with a diagnosis of fetal megacystis were retrieved from local databases, from the time at which registration in each database had started (between 2000 and 2014 at Erasmus Medical Center and Academic Medical Center, Amsterdam, and at University Medical Center, Maastricht; between 2004 and 2015 at University Medical Center Groningen, Groningen, and at Radboud University Medical Center, Nijmegen; and between 2007 and 2014 in the remaining centers). In the first trimester, fetal megacystis was defined as a fetal bladder with LBD of ≥ 7 mm, and in the second and third trimesters as an enlarged bladder failing to empty during an extended ultrasound examination lasting at least 40 min[2](#uog19182-bib-0002){ref-type="ref"}, [11](#uog19182-bib-0011){ref-type="ref"}.

In The Netherlands, all cases suspected of fetal megacystis are referred to the FMU of one of the eight academic hospitals for confirmation of the diagnosis and further investigation. Cases were referred after either a dating scan, first‐trimester scan, 20‐week anomaly scan or after a scan performed for other indications later in pregnancy. All cases had undergone a detailed anomaly scan, except for those pregnancies that did not reach the 18^th^ week of gestation (*n* = 142, including 115 terminated pregnancies and 27 miscarriages). Parents were counseled about the prognosis of the condition and informed about the possibility of *in‐utero* treatment. Vesicoamniotic shunt placement was only offered to chromosomally normal male fetuses with isolated signs of LUTO and with concomitant oligohydramnios.

For each case, prenatal data regarding gestational age (GA) at diagnosis, LBD and associated ultrasound findings were retrieved. The LBD was obtained from a midsagittal view of the fetus, by measuring the distance from the fetal bladder dome to the bladder neck. Ultrasound findings typically associated with LUTO, such as hydronephrosis, abnormal renal cortical appearance, keyhole sign and oligohydramnios (with eventual compression deformities), were not regarded as associated ultrasound anomalies. Nuchal translucency (NT) was considered increased if it was greater than the 95^th^ percentile according to GA[12](#uog19182-bib-0012){ref-type="ref"}. For cases referred in the first trimester of pregnancy, we considered NT measured at referral, while in fetuses referred later in pregnancy, we collected the NT measurement retrospectively.

All available postmortem examinations and postnatal investigations were reviewed in order to establish a final diagnosis. LUTO was defined as a bladder outlet obstruction caused by urethral valves, urethral stenosis or urethral atresia. The term anorectal malformation (ARM) was used to describe a group of complex congenital anomalies characterized by an abnormal development of the urorectal septum, resulting in congenital abnormalities of the distal anus, rectum and genitourinary tract[13](#uog19182-bib-0013){ref-type="ref"}. In this group, cloacal dysgenesis or cloacal malformation was characterized by the absence of anal, genital and urinary orifices[14](#uog19182-bib-0014){ref-type="ref"}. VACTERL association was diagnosed if three of the following criteria were met: vertebral defects, anal atresia/imperforate anus, cardiovascular anomalies, tracheoesophageal fistula or esophageal atresia, renal anomalies and limb defects (including radial anomalies) in at least two of the three regions involved (thorax, pelvis/lower abdomen and limb)[15](#uog19182-bib-0015){ref-type="ref"}. Caudal regression spectrum was defined as the presence of abnormalities at the level of the caudal spinal segments, ranging from minor sacrococcygeal malformations to complete absence of sacrum and lumbar spine[16](#uog19182-bib-0016){ref-type="ref"}. Omphalocele‐exstrophy‐imperforate anus‐spinal defect (OEIS) complex was diagnosed in cases of omphalocele associated with bladder exstrophy, imperforate anus and spinal defect[17](#uog19182-bib-0017){ref-type="ref"}. Infants without LUTO or other severe congenital abnormality or congenital syndrome were included in the group with normal urinary tract or isolated urological anomaly, such as vesicoureteral reflux or duplex collecting system. Neonatal death was defined as death of a liveborn during the first 28 completed days postpartum. In case of isolated LUTO, the postnatal renal function was evaluated based on the estimated glomerular filtration rate (eGFR); this was calculated using the Schwartz formula, taking into account the infant\'s length and the creatinine nadir in the first year of age[18](#uog19182-bib-0018){ref-type="ref"}.

RESULTS {#uog19182-sec-0007}
=======

During the study period, 541 pregnancies (25 twin and 516 singleton pregnancies) were referred to one of the eight FMUs in The Netherlands owing to the finding of fetal megacystis. Of the 541 pregnancies, 233 (43%) were referred before the 18^th^ week of gestation (early megacystis) and 308 (57%) at or after the 18^th^ week of gestation (late megacystis) (Figure [1](#uog19182-fig-0001){ref-type="fig"}). This study deals with structural anomalies, genetic syndromes and developmental or chromosomal abnormalities associated with fetal megacystis. Other outcome measures relative to this cohort have been reported on in different studies[4](#uog19182-bib-0004){ref-type="ref"}, [5](#uog19182-bib-0005){ref-type="ref"}, [6](#uog19182-bib-0006){ref-type="ref"}.

![Flowchart showing clinical diagnosis and outcome of 541 fetuses with fetal megacystis. IUFD, intrauterine fetal demise; LUTO, lower urinary tract obstruction; MCA, multiple congenital anomalies; PM, postmortem; TOP, termination of pregnancy.](UOG-53-779-g001){#uog19182-fig-0001}

Fetal megacystis was isolated (or solely associated with other signs of LUTO) in 360 (67%) pregnancies and associated with other abnormal ultrasound findings in 181 (33%). More than a single associated anomaly was found in 70 cases, while a total of 292 associated ultrasound findings were observed (Table [1](#uog19182-tbl-0001){ref-type="table"}). The most common associated ultrasound anomaly was increased NT (22%), followed by single umbilical artery (10%) and cardiac defect (10%).

###### 

Details of additional 292 abnormal ultrasound findings observed in 181 fetuses diagnosed with megacystis

  Ultrasound finding                                                        *n* (%)
  ------------------------------------------------------------------------ ----------
  Nuchal translucency ≥ 95^th^ centile                                      64 (22) 
  Single umbilical artery                                                   30 (10) 
  Cardiac defect                                                            30 (10) 
  Ventricular septal defect                                                  3 (1)  
  Umbilical cord cyst                                                       27 (9)  
  Spinal or skeletal anomaly                                                19 (6)  
  Sacrococcygeal teratoma                                                    1 (0.3)
  Abdominal wall defect                                                     18 (6)  
  Urogenital anomaly                                                        15 (5)  
  Intrauterine growth restriction                                            7 (2)  
  Macrosomia                                                                 6 (2)  
  Macroglossia                                                               1 (0.3)
  Central nervous system anomaly                                             5 (2)  
  Cleft lip/palate                                                           3 (1)  
  Fetal hydrops                                                              8 (3)  
  Diaphragmatic hernia                                                       3 (1)  
  Choroid plexus cyst                                                       15 (5)  
  Echogenic bowel                                                           11 (4)  
  Short long bones                                                           6 (2)  
  Ventriculomegaly                                                           2 (0.7)
  Echogenic intracardiac focus                                               2 (0.7)
  Miscellaneous syndromal marker[\*](#uog19182-note-0002){ref-type="fn"}    16 (5)  

More than one finding was present in some fetuses.

Including hypertelorism, strawberry skull, micrognathia and clubfoot.

Overall 188 (35%) pregnancies were terminated, 50 (9%) resulted in intrauterine demise, 68 (13%) in neonatal death and 235 (43%) children were alive beyond 28 days after birth. Of the terminated pregnancies, the parents did not consent to postmortem examination in 117 (62%) cases. Moreover, six cases were lost to follow‐up (Figure [1](#uog19182-fig-0001){ref-type="fig"}). Therefore, a final causal diagnosis was possible in 418 (77%) cases. These included 222 (53%) cases with isolated LUTO, 60 (14%) infants with a minor isolated urological anomaly or normal micturition at birth, and 136 (33%) 'syndromic' cases with miscellaneous chromosomal abnormality, genetic syndrome or developmental anomaly (Table [2](#uog19182-tbl-0002){ref-type="table"}). The latter group consisted of four categories: (1) fetuses with major chromosomal abnormality (*n* = 40); (2) fetuses with ARM (*n* = 32); (3) fetuses with macrosomia or overgrowth genetic syndrome (*n* = 10); and (4) cases with multiple congenital abnormalities or other miscellaneous genetic syndrome (*n* = 54). Table [3](#uog19182-tbl-0003){ref-type="table"} summarizes GA at referral, LBD, fetal gender, pregnancy outcome and findings at postnatal or postmortem investigation in the syndromic cases. The outcome and postnatal renal function of cases with isolated LUTO are reported in Table [4](#uog19182-tbl-0004){ref-type="table"}.

###### 

Final diagnosis and gestational age (GA) at initial diagnosis, in 418 pregnancies with fetal megacystis

  Final diagnosis                                                     *n* (%)    GA (weeks)
  ------------------------------------------------------------------ ---------- ------------
  LUTO                                                                222 (53)   22.6 ± 7 
  Normal micturition at birth or minor isolated urological anomaly     60 (14)   21.7 ± 10
  Miscellaneous congenital syndrome                                   136 (33)   18.8 ± 7 
  Major chromosomal abnormality                                        40 (10)   15.3 ± 4 
  Anorectal malformation                                               32 (8)    15.9 ± 5 
  Fetal macrosomia or overgrowth syndrome                              10 (2)    22.7 ± 8 
  MCA or other syndrome                                                54 (13)   20.0 ± 7 

GA is given as mean ± SD.

LUTO, lower urinary tract obstruction; MCA, multiple congenital anomalies.

###### 

Antenatal characteristics, outcome and postnatal/postmortem findings in pregnancies with fetal megacystis and associated chromosomal or developmental abnormalities or genetic syndrome

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Finding                                                                    GA at referral (weeks)    Mean LBD (mm)                 Cases with LUTO signs                              Oligo‐/an‐hydramnios                Male sex   Outcome               Associated anomalies at antenatal US                                Findings at postmortem/postnatal examination
  -------------------------------------------------------------------------- ------------------------ --------------- ---------------------------------------------------- ----------------------------------------------- ----------- --------------------- ------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Chromosomal abnormality*                                                                                                                                                                                                                                                                                                      

  Trisomy 18 or mosaicism (*n* = 24)                                         17\                            25                              21 (88)                                            7 (29)                       21 (88)    15 TOP; 9 PD          Increased NT, CHD, UCC, omphalocele, skeletal/spinal defect         CHD, agenesis of cerebellar vermis, omphalocele, clubfoot
                                                                             (12--29)                                                                                                                                                                                                                                            

  Trisomy 21 (*n* = 5)                                                       16\                            26                               3 (60)                                            3 (60)                        5 (100)   4 TOP; 1 PD           Increased NT, skeletal anomaly                                      NA
                                                                             (13--22)                                                                                                                                                                                                                                            

  Turner syndrome or mosaicism (*n* = 5)                                     15\                            15                               2 (40)                                            1 (20)                        2 (40)    3 TOP; 1 PD; 1 AL     UCC, increased NT                                                   Imperforate anus, facial dysmorphism, CHD
                                                                             (11--21)                                                                                                                                                                                                                                            

  Trisomy 13 (*n* = 3)                                                       12\                             9                               3 (100)                                           0 (0)                         3 (100)   3 TOP                 CHD, labiopalatoschisis, SUA, polydactyly                           NA
                                                                             (12--13)                                                                                                                                                                                                                                            

  Deletion 22q11 syndrome (*n* = 3)                                          25 (12--37)                    31                               3 (100)                                           1 (33)                        3 (100)   1 TOP; 2 AL           CHD                                                                 Unilateral renal agenesis, CHD, VUR

  Total (*n* = 40)                                                           17\                            23                              32 (80)                                           12 (30)                       34 (85)    26 TOP; 11 PD; 3 AL   Common features: increased NT                                       Common features: CHD
                                                                             (11--37)                                                                                                                                                                                                                                            

  *Additional chromosomal abnormality with doubtful clinical significance*                                                                                                                                                                                                                                                       

  46,XY, 1.9 Mb duplication, 19q13.33 *de novo* (*n* = 1)                    NA                             NA                               0 (0)                                             0 (0)                         1 (100)   AL                    UCC                                                                 Delayed motor development, muscular hypotonia, gastroesophageal reflux; ectopic testis, epiphyseal dysplasia, short stature

  46,XY, 22q11.2 microduplication + 14q31 duplication (*n* = 1)              37                             NA           1 (100)[\*](#uog19182-note-0005){ref-type="fn"}                       1 (100)                       1 (100)   AL                    None                                                                PUV, severe VUR (grades III--IV)

  46,XX, deletion 5q.35.2 (*n* = 1)                                          19                             NA            1 (100)[†](#uog19182-note-0006){ref-type="fn"}                       1 (100)                       0 (0)     AL                    None                                                                Tethered cord, neurogenic bladder, VUR, multidysplastic kidneys, psychomotor disability

  46,X, der (X) t (X; Y) (p22.33; p11.31) (*n* = 1)                          21                             13           1 (100)[\*](#uog19182-note-0005){ref-type="fn"}                       1 (100)                       1 (100)   AL                    None                                                                VUR, bilateral renal dysplasia, renal insufficiency, 46XX male

  46,XY, t (14;16) (q24.3; q24.1)pat (*n* = 1)                               22                             NA            1 (100)[‡](#uog19182-note-0007){ref-type="fn"}                       1 (100)                         NA      TOP                   Unilateral renal agenesis (left) and renal dysplasia (right)        Unilateral renal agenesis (left) and renal dysplasia (right)

  *Anorectal malformation*                                                                                                                                                                                                                                                                                                       

  VACTERL (*n* = 13)                                                         17\                            24                             10 (77)                                            10 (77)                       11 (85)    10 TOP; 3 PD          CHD, unilateral renal agenesis, increased NT, SUA, UCC, FEB         Anal atresia, cloacal anomaly, unilateral renal agenesis, CHD, colon‐vesical fistula, limb anomaly, esophageal atresia, tethered cord, spina bifida, vertebral defect
                                                                             (11--31)                                                                                                                                                                                                                                            

  Cloacal malformation (*n* = 6)                                             17\                            48                               4 (67)                                            3 (50)                        1 (17)    5 TOP; 1 PD           VSD, cystic hygroma, UCC                                            Cloacal anomaly
                                                                             (13--22)                                                                                                                                                                                                                                            

  OEIS (*n* = 7)                                                             12\                            19                               2 (29)                                            2 (29)                        5 (71)    6 TOP; 1 PD           Omphalocele, SUA, increased NT                                      Cloacal anomaly, cloacal exstrophy, limb anomaly, spina bifida, renal agenesis
                                                                             (11--14)                                                                                                                                                                                                                                            

  CRS (*n* = 4)                                                              14\                            25                               1 (25)                                            4 (100)                       2 (50)    3 TOP; 1 PD           Unilateral renal agenesis, sirenomelia, spina bifida, SUA           Sacral agenesis, hypoplasia of lower extremities
                                                                             (12--17)                                                                                                                                                                                                                                            

  Fraser syndrome (*n* = 2)                                                  21\                            68                               2 (100)                                           2 (100)                       1 (50)    2 TOP                 Overgrowth, hypertelorism, clubfoot, increased NT, renal agenesis   Renal agenesis, syndactyly, imperforate anus, facial dysmorphism
                                                                             (21--22)                                                                                                                                                                                                                                            

  Total (*n* = 32)                                                           16\                            29                              23 (72)                                           21 (66)                        20 (63)   26 TOP; 6 PD          Common features: SUA, increased NT, UCC, renal agenesis             Common features: imperforate anus/anal agenesis, cloacal anomaly, spinal defect, limb anomaly
                                                                             (11--22)                                                                                                                                                                                                                                            

  *Overgrowth syndrome or fetal macrosomia*                                                                                                                                                                                                                                                                                      

  BWS (*n* = 2)                                                              22 (21--22)                    35                               2 (100)                                           1 (50)                        2 (100)   1 TOP; 1 AL           Fetal overgrowth, macroglossia, hepatomegaly, skeletal dysplasia    PUV, skeletal dysplasia

  Sotos syndrome (*n* = 2)                                                   24\                            NA                               0 (0)                          1 (50)[§](#uog19182-note-0008){ref-type="fn"}    2 (100)   1 TOP; 1 AL           Polyhydramnios                                                      NA
                                                                             (17--30)                                                                                                                                                                                                                                            

  Unknown cause (*n* = 5)                                                    17\                            20                               2 (40)                         1 (20)[¶](#uog19182-note-0009){ref-type="fn"}    5 (100)   2 TOP; 3 AL           EFW \> 90^th^ centile                                               VUR, congenital megaureter
                                                                             (12--35)                                                                                                                                                                                                                                            

  Cantu syndrome (*n* = 1)                                                   21                             15                               1 (100)                        0 (0)[§](#uog19182-note-0008){ref-type="fn"}     1 (100)   1 AL                  Polyhydramnios, EFW \> 90^th^ centile                               VUR, facial dysmorphism, PAS

  Total (*n* = 10)                                                           22\                            27                               5 (50)                                            6 (60)                       10 (100)   4 TOP; 6 AL           Common features: fetal overgrowth, polyhydramnios                   Common features: VUR, PUV
                                                                             (12--35)                                                                                                                                                                                                                                            

  *Other miscellaneous syndrome*                                                                                                                                                                                                                                                                                                 

  MMIHS (*n* = 5)                                                            16\                            42                               5 (100)                                           1 (20)                         3 (60)   5 PD                  Increased NT, clubfoot                                              NA
                                                                             (12--21)                                                                                                                                                                                                                                            

  Smith--Lemli--Opitz syndrome (*n* = 2)                                     22\                            NA                               2 (100)                                           2 (100)                       2 (100)   1 TOP; 1 AL           Shortened long bones, increased NT                                  Urethral atresia, hypospadia, ureteropelvic stenosis, polydactyly, CHD, cleft palate, micrognathia
                                                                             (16--28)                                                                                                                                                                                                                                            

  Morris syndrome (*n* = 1)                                                  35                             57                               0 (0)                                             0 (0)                         1 (100)   AL                    None                                                                

  Ochoa syndrome (*n* = 1)                                                   33                             54                               0 (0)                                             0 (0)                         1 (100)   AL                    None                                                                

  Spinal muscular atrophy (*n* = 1)                                          16                             35          1 (100)[\*\*](#uog19182-note-0010){ref-type="fn"}                      0 (0)                         1 (100)   AL                    Increased NT, UCC, absent DV, hydrops                               Arthrogryposis, neurogenic bladder

  Marcus Gunn jaw winking syndrome (*n* = 1)                                 21                             NA                               0 (0)                                             0 (0)                         1 (100)   AL                    None                                                                PUV, VUR, duplex collecting system
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are given as mean (range) or *n* (%).

Keyhole sign, hydronephrosis, oligohydramnios.

Abnormal renal cortical appearance, oligohydramnios.

Keyhole sign, abnormal renal cortical appearance, hydronephrosis, oligohydramnios.

Plus one case of polyhydramnios.

Plus two cases of polyhydramnios.

Keyhole sign, abnormal renal cortical appearance.

AL, alive beyond 28 days after birth; BWS, Beckwith--Wiedemann syndrome; CHD, congenital heart defect; CRS, caudal regression syndrome; DV, ductus venosus; EFW, estimated fetal weight; FEB, fetal echogenic bowel; GA, gestational age; LBD, longitudinal bladder diameter; LUTO, lower urinary tract obstruction; MMIHS, megacystis‐microcolon‐intestinal hypoperistalsis; NA, not available; NT, nuchal translucency; OEIS, omphalocele‐exstrophy‐imperforate anus‐spinal defect; PAS, pulmonary artery stenosis; PD, perinatal death including intrauterine fetal demise and neonatal death; PUV, posterior urethral valves; SUA, single umbilical artery; TOP, termination of pregnancy; UCC, umbilical cord cyst; US, ultrasound; VSD, ventricular septal defect; VUR, vesicoureteral reflux.

###### 

Pregnancy outcome and postnatal renal function in 222 fetuses diagnosed with isolated lower urinary tract obstruction (LUTO)

  Outcome                                                              Value
  ---------------------------------------------------------------- -------------
  Termination of pregnancy                                            54 (24)
  Perinatal death[\*](#uog19182-note-0012){ref-type="fn"}             39 (18)
  Alive beyond 28 days after birth                                   129 (58)
  Cause of obstruction (*n* = 181)                                 
  Posterior urethral valves                                           83 (46)
  Urethral atresia                                                     5 (3)
  Urethral stenosis and other                                         93 (51)
  Postnatal renal function (*n* = 80)                              
  eGFR (mL/min/1.73 m^2^)                                           63 (3--162)
  Severely impaired renal function (eGFR \< 30 mL/min/1.73 m^2^)      16 (20)

Data are expressed as *n* (%) or median (range).

Perinatal death includes intrauterine demise and neonatal death.

eGFR, estimated glomerular filtration rate.

In total, 40 chromosomal abnormalities were diagnosed (Tables [2](#uog19182-tbl-0002){ref-type="table"} and [3](#uog19182-tbl-0003){ref-type="table"}), with a predominance of trisomy 18 (24 cases, including 22 with trisomy 18 and two with trisomy 18 mosaicisms), followed by trisomy 21 (five cases), Turner syndrome (five cases: one with Turner syndrome and four with Turner mosaicism), trisomy 13 (three cases) and deletion 22q11 (three cases). In the chromosomally abnormal fetuses, megacystis was diagnosed at a mean GA of 17 weeks and was associated with increased NT or other severe structural anomalies. Amniotic fluid volume was normal in 70% of cases. In addition, five fetuses presented with miscellaneous chromosomal abnormalities of uncertain clinical significance, but probably unrelated to the observed phenotypes (Table [3](#uog19182-tbl-0003){ref-type="table"}).

Thirty‐two cases presented with a wide spectrum of developmental abnormalities involving the anus, rectum and urogenital tract, and were classified as having ARM. This group included 13 fetuses with VACTERL associations, six with cloacal malformations, seven with OEIS complex, two with Fraser syndrome and four with caudal regression spectrum. In fetuses with ARM, megacystis was detected early in pregnancy (mean GA at referral, 16 weeks). In all cases with urethral and anal atresia, the fetal bladder was severely distended, with LBD (in mm) equal to or greater than twice the GA (in weeks). In cases of moderate bladder distension, with LBD lower than GA × 2 (mm), a spinal or vertebral anomaly was found either at the antenatal scan or at the postmortem examination. In this group, the amniotic fluid volume was reduced in 66% of cases.

Fetal macrosomia was detected in six cases and an overgrowth syndrome in four cases, which comprised two infants with Beckwith--Wiedemann syndrome (BWS) and two with Sotos syndrome. Five fetuses were diagnosed with megacystis‐microcolon‐intestinal hypoperistalsis syndrome (MMIHS), four of which had normal amniotic fluid volume during pregnancy. Moreover, a similar phenotype with intestinal hypoperistalsis and detrusor hypotonia was observed in one infant with Ochoa syndrome. Other miscellaneous genetic and structural anomalies observed in our cohort are reported in Table [3](#uog19182-tbl-0003){ref-type="table"}.

Based on the antenatal findings and final diagnosis in our cohort, a flowchart was designed to guide the differential diagnosis of fetal megacystis and rule out major genetic syndromes and developmental abnormalities (Figure [2](#uog19182-fig-0002){ref-type="fig"}).

![Practical guide for differential diagnosis of fetal megacystis. CHD, congenital heart defect; CRL, crown--rump length; CRS, caudal regression syndrome; GA, gestational age; LBD, longitudinal bladder diameter; LUTO, lower urinary tract obstruction; MMIHS, megacystis‐microcolon‐intestinal hypoperistalsis; NT, nuchal translucency; OEIS, omphalocele‐exstrophy‐imperforate anus‐spinal defect; SUA, single umbilical artery; UCC, umbilical cord cyst.](UOG-53-779-g002){#uog19182-fig-0002}

In our study population, 360 fetuses had isolated megacystis (megacystis without other associated ultrasound abnormality or solely with associated signs of LUTO). This subgroup of fetuses had a better outcome, as shown in Figure [3](#uog19182-fig-0003){ref-type="fig"}. Their GA at onset of oligo‐ or anhydramnios was related to the fetal outcome; this was 17 weeks in the pregnancies that were terminated (*n* = 116), 20 weeks in pregnancies that ended in intrauterine fetal demise (*n* = 19), 24 weeks in those that resulted in a neonatal death (*n* = 28) and 30 weeks in children that survived (*n* = 197). Among the 197 surviving children, LUTO was confirmed in 129 cases, while in 60, normal micturition or an isolated urological anomaly (including vesicoureteral reflux or duplex collecting system) was diagnosed. Impaired renal function (eGFR \< 60 mL/min/1.73m^2^) within the first year of age was observed in 36 children with confirmed LUTO and in only one child without LUTO, but with severe vesicoureteral reflux.

![Flowchart showing outcome of 360 fetuses with isolated megacystis. \*Includes fetuses without postnatal evidence of lower urinary tract obstruction (LUTO), but normal micturition, vesicoureteral reflux or duplex collecting system. eGFR, estimated glomerular filtration rate; GA, gestational age; IUFD, intrauterine fetal demise; TOP, termination of pregnancy.](UOG-53-779-g003){#uog19182-fig-0003}

DISCUSSION {#uog19182-sec-0008}
==========

This study shows that, although the main cause of fetal megacystis is LUTO, an enlarged fetal bladder can also be present as a concomitant finding in miscellaneous genetic syndromes, developmental anomalies and chromosomal abnormalities. The main problem in the work‐up of fetal megacystis remains its definition and the lack of a standardized antenatal management approach[3](#uog19182-bib-0003){ref-type="ref"}. In this study, we provide an overview of the underlying etiologies and propose a practical guide for the differential diagnosis of fetuses with isolated megacystis or associated bladder enlargement.

Fetal megacystis was an associated finding in one‐third of our cases. After exclusion of chromosomal anomalies, the most frequently observed complex anomaly was an ARM, diagnosed in 8% of cases. In this group, fetuses with a cloacal malformation typically presented with severe and early megacystis, with a LBD larger than twice the GA. This anomaly is typically suspected in female fetuses with distended bladder and, behind it, a single or septate anechoic area corresponding to the vagina[19](#uog19182-bib-0019){ref-type="ref"}, [20](#uog19182-bib-0020){ref-type="ref"}, [21](#uog19182-bib-0021){ref-type="ref"}, [22](#uog19182-bib-0022){ref-type="ref"}. In spite of a predominance in female fetuses, we confirm, similarly to other studies[14](#uog19182-bib-0014){ref-type="ref"}, [19](#uog19182-bib-0019){ref-type="ref"}, that a cloacal malformation can also occur in male fetuses.

In 81% (26/32) of cases, ARM was part of multisystemic anomalies, such as VACTERL association, caudal regression spectrum, OEIS complex and Fraser syndrome. Similarly to Bornes *et al*.[11](#uog19182-bib-0011){ref-type="ref"}, we diagnosed VACTERL association and OIES complex in 20/418 (5%) of fetuses with fetal megacystis. VACTERL association is rarely diagnosed prenatally as the key features, such as anorectal and esophageal atresia (with absence of gastric bubble) are not easily detected prenatally[20](#uog19182-bib-0020){ref-type="ref"}, [21](#uog19182-bib-0021){ref-type="ref"}. In fact, absent or small stomach bubble is present in less than 10% of fetuses with esophageal atresia, owing to the presence of a tracheoesophageal fistula in the majority of cases[22](#uog19182-bib-0022){ref-type="ref"}. Similarly, absence of the perianal muscular complex in anorectal atresia is more commonly observed from 23 weeks\' gestation onwards and is not seen on the routine 20‐week scan[23](#uog19182-bib-0023){ref-type="ref"}, [24](#uog19182-bib-0024){ref-type="ref"}. In light of this study, we advocate that this condition be considered in the differential diagnosis of fetal megacystis, particularly if this occurs early in pregnancy with associated spinal, renal, limb or cardiac defects, single umbilical artery and umbilical cord cysts.

A second striking result of this study was the association of fetal megacystis with fetal macrosomia and with overgrowth syndromes, such as BWS and Sotos syndrome. In this group, megacystis may occur owing to a variety of causes such as obstructive polyps or posterior urethral valves in BWS[25](#uog19182-bib-0025){ref-type="ref"}, [26](#uog19182-bib-0026){ref-type="ref"}, [27](#uog19182-bib-0027){ref-type="ref"} and urethral stenosis in Sotos syndrome[28](#uog19182-bib-0028){ref-type="ref"}, or simply owing to polyuria. Typical antenatal ultrasound features of overgrowth syndromes have been described in detail before[29](#uog19182-bib-0029){ref-type="ref"}, and Vora and Bianchi proposed an algorithm to assist in the differential diagnosis of these syndromes[30](#uog19182-bib-0030){ref-type="ref"}. However, it should be borne in mind that overgrowth/macrosomia is rarely detected at the 20‐week scan and in the majority of cases the diagnosis occurs only after birth[30](#uog19182-bib-0030){ref-type="ref"}.

MMIHS was observed in 1% of cases in our cohort. This is a rare syndrome with poor prognosis characterized by a distended non‐obstructed bladder and intestinal hypoperistalsis[31](#uog19182-bib-0031){ref-type="ref"}. MMIHS is considered the most severe form of a spectrum of chronic intestinal pseudo‐obstructive disorders, such as the more common Hirschsprung\'s disease[31](#uog19182-bib-0031){ref-type="ref"}. The genetic basis of MMIHS has been ascribed to a number of different autosomal dominant and recessive mutations (*ACTG2*, *MYH11* and *LMOD1* genes)[32](#uog19182-bib-0032){ref-type="ref"}, [33](#uog19182-bib-0033){ref-type="ref"}, [34](#uog19182-bib-0034){ref-type="ref"}. In our study, this syndrome was suspected in only one affected fetus, while in the remaining cases LUTO was suspected. Prenatal diagnosis of MMIHS is indeed challenging and successful in less than one‐third of cases[35](#uog19182-bib-0035){ref-type="ref"}. However, discriminating MMIHS from LUTO remains crucial because MMIHS, although usually lethal, is rarely associated with significant renal impairment and thus any form of prenatal bladder drainage would be inappropriate[35](#uog19182-bib-0035){ref-type="ref"}.

The majority of MMIHS cases in our cohort presented with typical LUTO signs, such as megacystis and bilateral hydronephrosis. This further highlights the importance of considering MMIHS in the differential diagnosis of megacystis with LUTO. To date, this syndrome is typically suspected in female fetuses with coexisting megacystis and normal to increased amniotic fluid volume. However, in our cohort, fetal gender was not so relevant in predicting MMIHS, as three out of five cases were male fetuses. This is in keeping with a systematic review showing that 32% of MMHIS cases occur in boys and polyhydramnios is reported in only 27% of cases[35](#uog19182-bib-0035){ref-type="ref"}. For this purpose, we suggest a new clinical score to discriminate LUTO from cases with non‐obstructive megacystis (such as MMIHS), and Tuzovic *et al*.[35](#uog19182-bib-0035){ref-type="ref"} suggested a set of typical ultrasound signs of MMIHS, such as dilated fetal stomach, large atonic bladder with a thin wall and dilated bowel loops in the third trimester. As the gastrointestinal anomalies of MMIHS are scarcely amenable to ultrasound diagnosis, fetal magnetic resonance imaging can be of help in detecting microcolon and dilated esophagus[36](#uog19182-bib-0036){ref-type="ref"}. Although the genetic basis of MMHIS is heterogeneous and most cases are sporadic, we would recommend that, in the presence of the abovementioned criteria, genetic testing for MMHIS should be carried out, especially before prenatal bladder drainage is considered.

In the subgroup of fetuses with isolated megacystis, our outcome data support the findings of Bornes *et al*., with about half (55%) surviving and about one in six (15%) being diagnosed with vesicoureteral reflux after birth[11](#uog19182-bib-0011){ref-type="ref"}. However, the most important message of this study is that fetal megacystis can be the common denominator of many conditions other than LUTO, including complex conditions with a poor prognosis such as chromosomal abnormalities or ARM, while it can also be merely a sign of isolated urological anomalies with an overall good prognosis.

A limitation of this study is its retrospective nature. In fact, we describe a set of fetal abnormalities and syndromes diagnosed based on local protocols without following a systematic protocol for invasive testing or genetic analysis. This implies that other syndromic cases may have been overlooked, resulting in an underestimation of the real prevalence of syndromal associations.

In conclusion, this study provides an overview of a range of disorders associated with fetal megacystis and proposes a practical guide for the prenatal differential diagnosis of genetic syndromes and chromosomal and developmental abnormalities in pregnancies presenting with fetal megacystis, focusing on the morphological examination of the fetus. This may be of help in the antenatal work‐up and counseling of fetal megacystis.
